ArcherDX, Inc has discovered a new next-generation sequencing (NGS) device to detect Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusions that leads to the formation and growth of cancer.
The role of Companion Diagnostic (CDx) is to indicate Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusions, thus helping to prevent the growth of cancers.
Usually it’s very tough to detect NTRK gene fusions in cancers, hence with the help of newly designed next-generation sequencing technology which makes use of RNA to provide sensitive NTRK fusion detection makes easier without requiring prior knowledge of fusion partners for any solid tumour.
The newly developed NGS technology makes use of advanced Anchored Multiplex PCR (AMP) chemistry which captures DNA, RNA or ctDNA from both blood and tissue samples irrespective of the location of the tumour.
This breakthrough technology allows diagnostics for patients in community and regional settings where there is shortage of infrastructure and expertise to implement sophisticated genomic analysis.
ArcherDX recently announced a collaboration to develop an NGS-based CDx for a TRK inhibitor.
Next-generation sequencing (NGS) device also received the U.S. Food and Drug Administration’s (FDA’s) breakthrough device designation.
